tiprankstipranks
TLRY Earnings: Tilray Gains after Q4 EPS Beat
Market News

TLRY Earnings: Tilray Gains after Q4 EPS Beat

Story Highlights

Earnings per share came in at $0.04, which beat analysts’ consensus estimate of -$0.02 per share.

Shares of Tilray (TLRY) gained in after-hours trading after the cannabis company reported earnings for its fourth quarter of Fiscal Year 2024. Earnings per share came in at $0.04, which beat analysts’ consensus estimate of -$0.02 per share.

Don't Miss Our Christmas Offers:

Sales increased by 24.8% year-over-year, with revenue hitting $229.88 million. This jump in revenue was mainly driven by a 137% surge in Beverage-alcohol sales from $32.3 million to $76.7 million, which were due to product innovations and the acquisitions of several beer brands from Anheuser-Busch (BUD).

Investor Sentiment for TLRY Stock

The sentiment among TipRanks investors is currently very negative. Out of the 746,050 portfolios tracked by TipRanks, 0.5% hold TLRY stock. In addition, the average portfolio weighting allocated towards TLRY among those who do have a position is 3.78%. This suggests that investors of the company are fairly confident about its future.

However, in the last 30 days, 1.8% of those holding the stock decreased their positions. As a result, the stock’s sentiment is below the sector average, as demonstrated in the following image:

Is TLRY Stock a Good Buy?

Turning to Wall Street, analysts have a Moderate Buy consensus rating on TLRY stock based on one Buy and two Holds assigned in the past three months, as indicated by the graphic below. After a 28% decline in its share price over the past year, the average TLRY price target of $2.35 per share implies 28.42% upside potential. However, it’s worth noting that estimates will likely change following today’s earnings report.

See more TLRY analyst ratings

Related Articles
TheFlyUnusually active option classes on open December 24th
TheFlyUnusually active option classes on open December 23rd
TheFlyRising High: Exclusive talk with biopharma company HMNC Brain Health
Go Ad-Free with Our App